BioCentury
ARTICLE | Clinical News

Merck KGaA's tepotinib meets in two Phase Ib/II trials for advanced HCC

July 13, 2018 7:13 PM UTC

Merck KGaA (Xetra:MRK) said once-daily oral tepotinib (MSC2156119J) as first- and second-line treatment each met the primary endpoints in the Phase II portions of two open-label Phase Ib/II trials to treat advanced c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)-positive hepatocellular carcinoma (HCC) with Child-Pugh Class A liver function. Data were presented at the American Society of Clinical Oncology meeting in Chicago and Merck plans to present additional data at a medical conference this year.

Data from 90 patients in the Phase II portion of an Asian Phase Ib/II trial showed tepotinib as a first-line treatment met the primary endpoint of improving time to progression as assessed by an independent review committee vs. Nexavar sorafenib...